2023
Survival analysis of patients treated at oncology practices with more aggressive end-of-life practice patterns.
Canavan M, Wang X, Ascha M, Miksad R, Showalter T, Calip G, Gross C, Adelson K. Survival analysis of patients treated at oncology practices with more aggressive end-of-life practice patterns. Journal Of Clinical Oncology 2023, 41: 6562-6562. DOI: 10.1200/jco.2023.41.16_suppl.6562.Peer-Reviewed Original ResearchReal-world overall survivalSystemic anticancer therapySurvival analysisNon-small cell lungCox proportional hazards modelPractice-level factorsRenal cell carcinomaProportional hazards modelCommon cancer typesDe-identified databaseElectronic health recordsAdvanced diseaseAdult patientsHazard ratioMetastatic diseaseMost patientsOverall survivalSurvival benefitSystemic treatmentAggressive endPrimary outcomeCell carcinomaCell lungPrimary exposureCancer patientsCurrent use of the National Surgical Quality Improvement Program surgical risk calculator in academic surgery: a mixed-methods study
Miller S, Azar S, Farrelly J, Salzman G, Broderick M, Sanders K, Anto V, Patel N, Cordova A, Schuster K, Jones T, Kodadek L, Gross C, Morton J, Rosenthal R, Becher R. Current use of the National Surgical Quality Improvement Program surgical risk calculator in academic surgery: a mixed-methods study. Surgery In Practice And Science 2023, 13: 100173. PMID: 37502700, PMCID: PMC10373440, DOI: 10.1016/j.sipas.2023.100173.Peer-Reviewed Original ResearchNSQIP Surgical Risk CalculatorSurgical Risk CalculatorNonelective casesRisk calculatorNational Surgical Quality Improvement Program Surgical Risk CalculatorHigh-risk patientsGeneral clinical practiceSpecific clinical scenariosCross-sectional studyElectronic health recordsFrail patientsPrimary outcomeHalf of respondentsPreoperative assessmentContemporary surgical practiceClinical practiceClinical scenariosSurgical practicePast monthPatientsSurgeonsTraining statusSurrogate consentPotential interventionsHealth recordsPerceived appropriateness of assessing for health-related socioeconomic risks among adult patients with cancer
Vu M, Boyd K, De Marchis E, Garnache B, Gottlieb L, Gross C, Lee N, Lindau S, Mun S, Winslow V, Makelarski J. Perceived appropriateness of assessing for health-related socioeconomic risks among adult patients with cancer. Cancer Research Communications 2023, 3: 521-531. PMID: 37020993, PMCID: PMC10069714, DOI: 10.1158/2767-9764.crc-22-0283.Peer-Reviewed Original ResearchConceptsElectronic health recordsHealth care settingsAdult patientsCare settingsHealth care-related factorsCare-related factorsPerceptions of patientsAmerican Cancer SocietyFisher's exact testNational Cancer InstituteMost patientsOutpatient clinicCancer SocietySocioeconomic riskCancer InstitutePatientsExact testSelf-administered surveyEHR documentationSignificant associationSociodemographic characteristicsClinical settingCancerHealthcare settingsCancer treatment
2021
Differences by race in systemic oncologic end-of-life (EOL) care among patients with cancer.
Adelson K, Wang X, Ascha M, Miksad R, Showalter T, Calip G, Gross C, Canavan M. Differences by race in systemic oncologic end-of-life (EOL) care among patients with cancer. Journal Of Clinical Oncology 2021, 39: 137-137. DOI: 10.1200/jco.2020.39.28_suppl.137.Peer-Reviewed Original ResearchBlack patientsWhite patientsAggressive EOL careRetrospective cohort studyPractice-level factorsPractice-level characteristicsRacial differencesDe-identified databaseLogistic regression modelsAnti-cancer therapyElectronic health recordsImmunotherapy eraCohort studyICI useOncologic treatmentPayer cohortHigh patientEOL careAdjusted ratesOutcome measuresEOL treatmentMedicaid coveragePatientsPhysician ratioRoutine practiceTrends in end-of- life (EOL) systemic oncologic treatment in contemporary clinical practice: Insights from real-world data.
Canavan M, Wang X, Ascha M, Miksad R, Showalter T, Calip G, Gross C, Adelson K. Trends in end-of- life (EOL) systemic oncologic treatment in contemporary clinical practice: Insights from real-world data. Journal Of Clinical Oncology 2021, 39: 253-253. DOI: 10.1200/jco.2020.39.28_suppl.253.Peer-Reviewed Original ResearchDay of deathReal-world practiceTraditional chemotherapyCancer treatmentStudy periodPractice-level factorsOverall healthcare utilizationSystemic cancer treatmentRates of chemotherapyDays of lifeDe-identified databaseContemporary clinical practiceLogistic regression modelsElectronic health recordsCancer care organizationsSystemic therapySystemic treatmentOncologic treatmentHealthcare utilizationImmune therapyTargeted therapyStratified analysisHigher total costsLife careOncolytic therapyHow did the COVID crisis affect use of neoadjuvant therapy for patients with breast cancer?
Chagpar A, Lannin D, Mougalian S, Berger E, Gross C, Horowitz N, Sanft T, DiGiovanna M, Golshan M, Pusztai L. How did the COVID crisis affect use of neoadjuvant therapy for patients with breast cancer? Journal Of Clinical Oncology 2021, 39: e18708-e18708. DOI: 10.1200/jco.2021.39.15_suppl.e18708.Peer-Reviewed Original ResearchUse of NTNeoadjuvant therapyEarly pandemic periodBreast cancerNon-metastatic breast cancerPractice settingsEarly pandemicFlatiron Health databaseNeoadjuvant endocrine therapyTechnology-enabled abstractionSame period one yearSimilar clinicopathologic featuresLongitudinal electronic health recordsPeriod one yearElectronic health recordsTNBC subsetEndocrine therapyPatient ageTN patientsClinicopathologic featuresContemporary cohortClinical stageCancer clinicCancer managementHigh risk
2019
Chromosome 1 abnormalities and clinical outcomes in multiple myeloma in the era of novel agents.
Giri S, Huntington S, Wang R, Zeidan A, Podoltsev N, Gore S, Ma X, Gross C, Davidoff A, Neparidze N. Chromosome 1 abnormalities and clinical outcomes in multiple myeloma in the era of novel agents. Journal Of Clinical Oncology 2019, 37: 8044-8044. DOI: 10.1200/jco.2019.37.15_suppl.8044.Peer-Reviewed Original ResearchOverall survivalMultiple myelomaPerformance statusMultivariable Cox survival analysisMedian overall survivalPoor performance statusLines of therapyKaplan-Meier methodCox regression analysisDays of diagnosisWorse overall survivalCox survival analysisLog-rank testReal-world treatmentCommon genetic mutationsHigh-risk mutationsSitu hybridization testingElectronic health recordsISS stageReal-world practiceMedian ageMeier methodOS independentPrimary outcomeSpecific regimens